Hepion Pharmaceuticals to Highlight AI-POWR™ at the 2023 CSPS Annual Symposium: The Next Frontiers in Pharmaceutical Sciences
24 Mai 2023 - 10:45PM
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage
biopharmaceutical company focused on artificial Intelligence
(“AI”)-assisted therapeutic drug development for the treatment of
non-alcoholic steatohepatitis (“NASH”), fibrotic diseases,
hepatocellular carcinoma (“HCC”), and other chronic diseases,
announces that its Senior Vice President for Clinical Pharmacology
and Analytics, Patrick Mayo, PhD, and its Quantitative Systems
Pharmacologist, Caroline Zhao, PharmD, will present at the 2023
Canadian Society for Pharmaceutical Sciences (“CSPS”) Annual
Symposium being held in Toronto, Canada from May 24 to May 26,
2023.
Presentation Details
Title: Simulation in drug
development: Clinical Pharmacology, Quantitative Systems
Pharmacology Artificial Intelligence and Beyond?
Date: Friday, May 26, 2023
Session: 9:00 – 11:00 AM ET
SESSION 6: AI and Computer Technology in the Sciences
Dr. Mayo commented, “Artificial intelligence and
machine learning are here, and are being integrated into drug
development. AI-POWR™ is Hepion’s proprietary AI/ML platform
designed to speed up drug development by detecting a priori
patients who will respond to our lead compound, rencofilstat. CSPS
has graciously allowed us the opportunity to describe the
integration of AI-POWR™ into all aspects of our clinical
pharmacological programs.”
A copy of the presentation will be accessible on
the Company’s website at www.hepionpharma.com under
“Publications” in the Pipeline section.
About Hepion
Pharmaceuticals
The Company's lead drug candidate, rencofilstat,
is a potent inhibitor of cyclophilins, which are involved in many
disease processes. Rencofilstat has been shown to reduce liver
fibrosis and hepatocellular carcinoma tumor burden in experimental
disease models and is currently in Phase 2 clinical development for
the treatment of NASH. In November 2021, the FDA granted Fast Track
designation for rencofilstat for the treatment of NASH. That was
followed in June 2022 by the FDA’s granting of Orphan Drug
designation to rencofilstat for the treatment of HCC.
Hepion has created a proprietary AI platform,
called AI-POWR™, which stands for Artificial
Intelligence - Precision
Medicine; Omics (including genomics, proteomics,
metabolomics, transcriptomics, and lipidomics);
World database access; and
Response and clinical outcomes. Hepion intends to
use AI-POWR™ to help identify which NASH patients will best respond
to rencofilstat, potentially shortening development timelines and
increasing the observable differences between placebo and treatment
groups. In addition to using AI-POWR™ to drive its ongoing NASH
clinical development program, Hepion intends to use the platform to
identify additional potential indications for rencofilstat to
expand the company's footprint in the cyclophilin inhibition
therapeutic space.
For further information, please contact:
Stephen KilmerHepion Pharmaceuticals Investor
RelationsDirect: (646) 274-3580skilmer@hepionpharma.com
Hepion Pharmaceuticals (NASDAQ:HEPA)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Hepion Pharmaceuticals (NASDAQ:HEPA)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024